Progyny, Inc. — Healthcare Plans. Scored on the same transparent model behind the daily rankings.
★
PGNY
Progyny, Inc. · Healthcare Plans
FCF$178mC
Rev+5.5%C+
D/E0.05A-
P/E28.9xB
PEG2.78C
70.7Score
$26.57$2.0B
1Y Target$33.82Analyst consensus · 11 analysts
5Y Target$49.51Compound horizon
10Y Target$73.45Long-dated conviction
FCF$178mTTMC
FCF $178m — modest; watch for margin expansion
Rev+5.5%TTM YoYC+
Revenue +5.5% — steady but below market-beating range
D/E0.05A-
D/E 0.05 — less debt than most Healthcare peers (≈25th pctile)
P/E28.9xB
P/E 28.9 — near the Healthcare median (≈60th pctile)
PEG2.78proxyC
PEG 2.78 — expensive relative to growth rate · PEG proxy: P/E ÷ revenue growth % (true PEG requires forward EPS estimates, not in Finnhub free tier).
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 70.7
Quality0.85
Growth0.68
Value0.61
Why this score
Buying back stock
Durable high returns
Entry · Margin of safety
52-week rangeMid-range
20% off the 12-month high
vs DCF fair value32% belowest. fair value ~$39
What the price assumes: free cash flow compounding at ~-3% a year for the next decade — vs the ~10% a year our model projects from current growth and analyst estimates.
Quality signals · context only
Gross profitability45% · A-gross profit ÷ total assets (Novy-Marx)
ROIC19.5% · A-return on invested capital — not score-weighted
Model-generatedGenerated by the Bull Rankings model from this company's reported fundamentals, and checked against the figures shown above.
Why now
Healthcare Plans · market cap $2.0b. 20% off the 52-week high of $33.06. 11 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $33.82 (implying +27% upside).
Moat
ROE 17% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong.
Risk
Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
Horizon
1-3 yr $33.82 (11-analyst consensus) — fundamentals + valuation re-rating. 5 yr $49.51 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $73.45 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
PGNY vs the Top Picks average
Pillar
PGNY
Book avg
Diff
Quality
0.85
0.84
in line
Growth
0.68
0.92
-0.23
Value
0.61
0.75
-0.14
Averaged across the 30 names in today's Top Picks (mean score 82.9). A name can beat these averages and still be absent from the book — it also applies concentration limits.
Score history · PGNY
Trend
-3.6 over 39 daily scores
From 74.3 (Jun 22) → 70.7 (now)
One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Position sizing · PGNY
$
%
%
Shares to buy
75
Position size
$1,993
4.0% of portfolio
Stop price
$19.93
25% below $26.57
$ at risk if stopped
$498.19
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Progyny, Inc. (PGNY): score, valuation & FAQ
Progyny, Inc. (PGNY) is a Healthcare Plans company that scores 70.7 out of 100 on the Bull Rankings quality-growth model — a solid, above-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are D/E (A-). On valuation, PGNY sits about 32% below our discounted-cash-flow fair value (a margin of safety) — the current price implies roughly -3% annual free-cash-flow growth over the next decade.
Is PGNY a good stock to buy?
Bull Rankings scores PGNY 70.7 out of 100 on its quality-growth model, which is a solid, above-average reading. That is driven by D/E (A-). A score is a quantitative screen of Progyny, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does PGNY score 70.7 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). PGNY earns its highest marks on D/E (A-). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is PGNY overvalued or undervalued?
Based on $26.57, PGNY sits about 32% below our discounted-cash-flow fair value (a margin of safety) — the current price implies roughly -3% annual free-cash-flow growth over the next decade. It trades at a 28.9x× P/E (graded B). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in PGNY?
Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.